Vertex Pharmaceuticals: Guggenheim maintains a 'Buy' Rating, The Target Price is $546

Guggenheim maintains 'Buy' rating on Vertex Pharmaceuticals(VRTX).

The target price is $546, compare with $558 previously.

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-08-06	Guggenheim	Maintains	Buy	Buy	$546	$558
2025-08-05	UBS	Maintains	Buy	Buy	$553	$582
2025-08-05	BMO Capital	Maintains	Outperform	Outperform	$530	$557
2025-08-05	Truist Securities	Maintains	Buy	Buy	$490	$520
2025-08-05	Cantor Fitzgerald	Maintains	Overweight	Overweight	$485	$535
2025-07-14	JP Morgan	Maintains	Overweight	Overweight	$517	$515

[Recent Earning Results] Vertex Pharmaceuticals posted the Q2 of its 2025 financial results on 8/5/2025, reporting total revenue of USD 5734.90 million in the first half of the year, up 7.47% from USD 5336.20 million year over year, reporting net income of USD 1679.20 million in the first half of the year, compare with USD -2494.00 million in the same period last year.

[Company Profile] Vertex Pharmaceuticals Incorporated was incorporated in Massachusetts in 1989. The company is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. The Company's two products are: KALYDECO (ivacaftor), which the Company markets in the United States and international markets for the treatment of patients six years of age and older with cystic fibrosis ("CF"), who have the G551D mutation in their cystic fibrosis transmembrane conductance regulator ("CFTR") gene, and INCIVEK (telaprevir), which is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus ("HCV") infection.